Citron’s Andrew Left Tight-Lipped On Valeant Position

0
1
Citron Andrew Left Valeant


Citron Research executive editor Andrew Left, explains his trading is not relevant to the Valeant story.

Citron’s Andrew Left tight-lipped on Valeant position

Citron’s Left: I put out info that was true

Citron Research executive editor Andrew Left, addresses Valeant Pharmaceuticals’ critical response to his report on the company.

This fund run by a SAC Capital alum bought restaurant stocks amid the pandemic

restaurantPrentice Capital Management was up 6.6% for the first four months of the year, compared to the S&P 500's 9.3% decline and the Russell 2000's 21.1% decline. The HFRX Equity Hedge Index was down 9.4% for the quarter. Q1 2020 hedge fund letters, conferences and more Gross and net exposures In his first-quarter letter to Read More

Citron: Not contacted by SEC

Citron Research executive editor Andrew Left, discusses the company’s strategy with the Valeant story and the Enron analogy.

Citron: Valeant should be the focus, not us

Citron Research executive editor Andrew Left, discusses the company’s strategy with the Valeant story in an effort to walk away from the story.

Citron: Easier to pass Citron story to mainstream media

Citron Research executive editor Andrew Left, discusses the company’s strategy with the Valeant story.